Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VVZ-149 in Healthy Older Male Volunteers
NCT02333318Phase 1Completed
- Sponsor
- Vivozon
- Start
- Jul 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of opiranserin in postoperative pain (3 arms), sponsored by Vivozon. Primary endpoint: Dose-limiting toxicity and maximum tolerated dose at 8 days. Started Jul 2014; status: completed.
02
Drugs
opiranserin
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02333318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333318.